Literature DB >> 106967

alpha-L-iduronidase, beta-D-glucuronidase, and 2-sulfo-L-iduronate 2-sulfatase: preparation and characterization of radioactive substrates from heparin.

J J Hopwood.   

Abstract

Radioactive disaccharide substrates for alpha-L-iduronidase, beta-D-glucuronidase, and 2-sulfo-L-iduronate 2-sulfatase have been prepared from heparin by deaminative cleavage followed by reduction with NaBT4. Six disaccharides were isolated from this reaction mixture and identified. Acid hydrolysis of the major disaccharide, O-(alpha-L-idopyranosyluronic acid 2-sulfate)-(1 linked to 4)-(2,5-anhydro-D-mannitol-l-t 6-sulfate (IdAs--Ms), produced 48% of O-(alpha-L-idopyranosyluronic acid)-(1 linked to 4)-(2,5-anhydro-D-mannitol-l-t 6-sulfate) (IdA--Ms) and 25% of O-(alpha-L-idopyranosyluronic acid)-(1 linked to 4)-2,5-anhydro-D-mannitol-l-t. The most-sensitive substrate for determining alpha-L-iduronidase activity was IdA--Ms which, when incubated with leucocyte and skin-fibroblast homogenates prepared from patients having a deficiency of alpha-L-iduronidase (Mucopolysaccharidosis Type I; MPS-I), was hydrolysed to yield 2,5-anhydro-D-mannitol-l-t 6-sulfate at a rate 50-times less than that found for normal control-preparations. Similarly, O-(beta-D-glucopyranosyluronic acid)-(1 linked to 4)-(2,5-anhydro-D-mannitol-l-t 6-sulfate) was degraded by whole-cell homogenates prepared from beta-D-glucuronidase-deficient (Mucopolysaccharidosis, Type VII) fibroblasts, to yield 2,5-anhydro-D-mannitol-l-t 5-sulfate at a rate 60-times less that that found for MPS-I and normal control-preparations. IdAs--Ms was degraded by 2-sulfo-L-iduronate 2-sulfatase at a rate more than 45-times greater than that found for O-(alpha-L-idopyranosyluronic acid 2-sulfate)-(1 linked to 4)-2,5-anhydro-D-mannitol-l-t. C-6 Sulfation of the anhydro-D-mannitol-l-t residue is an important structural determinant in the mechanism of action of both alpha-L-iduronidase and 2-sulfo-L-iduronate 2-sulfatase on disaccharide substrates.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 106967     DOI: 10.1016/s0008-6215(00)85765-1

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  19 in total

1.  Germline and somatic mosaicism in a female carrier of Hunter disease.

Authors:  R Froissart; I Maire; V Bonnet; T Levade; D Bozon
Journal:  J Med Genet       Date:  1997-02       Impact factor: 6.318

2.  Diagnosis of Maroteaux-Lamy syndrome by the use of radiolabelled oligosaccharides as substrates for the determination of arylsulphatase B activity.

Authors:  J J Hopwood; H Elliott; V J Muller; G T Saccone
Journal:  Biochem J       Date:  1986-03-15       Impact factor: 3.857

3.  Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties.

Authors:  J Bielicki; C Freeman; P R Clements; J J Hopwood
Journal:  Biochem J       Date:  1990-10-01       Impact factor: 3.857

4.  The iduronate sulphatase activities of cells and tissue fluids from patients with Hunter syndrome and normal controls.

Authors:  M F Dean
Journal:  J Inherit Metab Dis       Date:  1983       Impact factor: 4.982

5.  Human glucosamine-6-sulphatase deficiency. Diagnostic enzymology towards heparin-derived trisaccharide substrates.

Authors:  C Freeman; J J Hopwood
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

6.  Short synthetic sequence for 2-sulfation of alpha-L-iduronate glycosides.

Authors:  Sophie Blanchard; Frantisek Turecek; Michael H Gelb
Journal:  Carbohydr Res       Date:  2009-03-20       Impact factor: 2.104

7.  Human liver N-acetylglucosamine-6-sulphate sulphatase. Catalytic properties.

Authors:  C Freeman; J J Hopwood
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

8.  Human liver N-acetylglucosamine-6-sulphate sulphatase. Purification and characterization.

Authors:  C Freeman; P R Clements; J J Hopwood
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

9.  The clinical phenotype of two patients with a complete deletion of the iduronate-2-sulphatase gene (mucopolysaccharidosis II--Hunter syndrome).

Authors:  J E Wraith; A Cooper; M Thornley; P J Wilson; P V Nelson; C P Morris; J J Hopwood
Journal:  Hum Genet       Date:  1991-06       Impact factor: 4.132

10.  Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome.

Authors:  P J Wilson; G K Suthers; D F Callen; E Baker; P V Nelson; A Cooper; J E Wraith; G R Sutherland; C P Morris; J J Hopwood
Journal:  Hum Genet       Date:  1991-03       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.